Skip to Content

Fulgent Genetics, Inc.

Securities Class Action

  • Date:
  • 4/1/2026
  • Company Name:
  • Fulgent Genetics, Inc.
  • Stock Symbol:
  • FLGT
  • Status:
  • Investigating
  • Filing Date:
  • 9/20/2022

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices.

On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financial results.  Among other items, Fulgent provided lower-than-expected guidance for 2026, “reflect[ing] the impact of [its] largest customer moving a significant volume of its work in-house[.]” 

On this news, the price of Fulgent shares declined by $9.43 per share, or approximately 38.1%, from $24.76 per share on February 26, 2026 to close at $15.33 on February 27, 2026.

If you purchased or otherwise acquired Fulgent shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Fulgent Genetics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: